• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

PEMETREXED Drug Record

  • Summary
  • Interactions
  • Claims
  • PEMETREXED chembl:CHEMBL225072 ApprovedAntineoplasticImmunotherapy

    Alternate Names:

    NSC-698037
    ALIMTA
    LY-231514
    LY231514
    PEMETREXED
    LY-2315
    ALIMTA®
    pubchem.compound:446556
    rxcui:68446
    chemidplus:137281-23-3
    drugbank:00642
    chembl:CHEMBL225072

    Drug Info:

    FDA Approval 2004
    Drug Class small molecule
    Drug Indications Antineoplastic Agents
    FDA Approval not approved
    Drug Class Small molecule
    Drug Indications antineoplastic agent
    Drug Class antineoplastic agents
    Year of Approval 2004
    (7 More Sources)

    Publications:

    Pivot et al., 2001, Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck., Br. J. Cancer
    Kindler, 2002, Pemetrexed in pancreatic cancer., Semin. Oncol.
    Hanauske et al., 2001, Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors., Oncologist
    Mauritz et al., 2002, Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis., Biochem. Pharmacol.
    Adjei, 2001, Gemcitabine and Pemetrexed disodium in treating breast cancer., Oncology (Williston Park, N.Y.)
    Adjei, 2002, Pemetrexed in the treatment of selected solid tumors., Semin. Oncol.
    Giovannetti et al., 2005, Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells., Mol. Pharmacol.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Norman, 2001, Pemetrexed disodium (Eli Lilly)., Curr Opin Investig Drugs
    Schultz et al., Sequence dependence of Alimta (LY231514, MTA) combined with doxorubicin in ZR-75-1 human breast carcinoma cells., Anticancer Res.
    Molina et al., 2003, The role of Pemetrexed (Alimta , LY231514) in lung cancer therapy., Clin Lung Cancer
    Adjei, 2001, Gemcitabine and pemetrexed disodium combinations in vitro and in vivo., Lung Cancer
    Corrigan A et al., 2014, Pharmacogenetics of pemetrexed combination therapy in lung cancer: pathway analysis reveals novel toxicity associations., Pharmacogenomics J
    Jung M et al., 2013, Pharmacogenomic assessment of outcomes of pemetrexed-treated patients with adenocarcinoma of the lung., Yonsei Med J
    Chen et al., 2011, Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed., Lung Cancer
    Kasai et al., 2013, Thymidylate synthase gene copy number as a predictive marker for response to pemetrexed treatment of lung adenocarcinoma., Anticancer Res.
    Shimizu et al., 2012, Association between expression of thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase and efficacy of pemetrexed in advanced non-small cell lung cancer., Anticancer Res.
    Chamizo et al., 2015, Thymidylate synthase expression as a predictive biomarker of pemetrexed sensitivity in advanced non-small cell lung cancer., BMC Pulm Med
    Berman et al., 2000, The Protein Data Bank., Nucleic Acids Res.
    Gandara et al., 2017, A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer., J Thorac Oncol
    Pérez-Ramírez C et al., 2019, Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients., Pharmacogenomics J
    Chen JS et al., 2010, A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma., Anticancer Drugs
    Smit EF et al., 2009, Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer., J Clin Oncol
    Li et al., 2014, Response to pemetrexed rechallenge after acquired resistance of EGFR-TKI in a patient with advanced NSCLC., Lung Cancer
    Yang JC et al., 2020, A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis., J Thorac Oncol
    Wang L et al., 2011, Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-glycinamide ribonucleotide formyltransferase., J Med Chem
    Adjei AA et al., 2010, Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426., J Clin Oncol
    Goldman ID et al., 2002, Molecular, biochemical, and cellular pharmacology of pemetrexed., Semin Oncol
    Poklepovic et al., 2016, Phase I study of pemetrexed with sorafenib in advanced solid tumors., Oncotarget
    Wang L et al., 2015, 6-Substituted Pyrrolo[2,3-d]pyrimidine Thienoyl Regioisomers as Targeted Antifolates for Folate Receptor α and the Proton-Coupled Folate Transporter in Human Tumors., J Med Chem
    Mitchell-Ryan S et al., 2013, Discovery of 5-substituted pyrrolo[2,3-d]pyrimidine antifolates as dual-acting inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis: implications of inhibiting 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase to ampk activation and antitumor activity., J Med Chem
    Racanelli et al., 2009, Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition., Cancer Res.
    Lee et al., 2011, Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer., J Thorac Oncol
  • PEMETREXED   GART

    Interaction Score: 17.67

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target
    Trial Name Alimta

    PMIDs:
    11531245 12571811 11524555 10592235 11252887 12023793 15795320 11848474 11742712 14596699


    Sources:
    TdgClinicalTrial TEND

  • PEMETREXED   ATIC

    Interaction Score: 11.04

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    24256410 12571811 11524555 19549896


    Sources:
    DTC

  • PEMETREXED   FOLR3

    Interaction Score: 8.83

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24732178


    Sources:
    PharmGKB

  • PEMETREXED   SLC46A1

    Interaction Score: 6.62

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21879757 26317331


    Sources:
    DTC

  • PEMETREXED   DHFR

    Interaction Score: 5.3

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name Alimta
    Novel drug target Established target
    Trial Name -

    PMIDs:
    11531245 12571811 11524555 11841783 11252887 12023793 15795320 11752352 11763166 11848474 14596699 11742712 24732178 23709418


    Sources:
    TdgClinicalTrial ClearityFoundationClinicalTrial TEND PharmGKB

  • PEMETREXED   SLC19A1

    Interaction Score: 2.41

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21879757 24732178 19841321 12571805


    Sources:
    DTC PharmGKB

  • PEMETREXED   TYMS

    Interaction Score: 2.27

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name Alimta
    Novel drug target Established target
    Trial Name -

    PMIDs:
    21367480 23645741 23060591 26502926 11531245 12571811 11524555 11252887 12023793 15795320 11752352 11763166 11848474 14596699 11742712


    Sources:
    ClearityFoundationBiomarkers TdgClinicalTrial TEND CIViC

  • PEMETREXED   GGH

    Interaction Score: 1.77

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24732178


    Sources:
    PharmGKB

  • PEMETREXED   MTHFR

    Interaction Score: 0.88

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29662106 24732178 20634689 19307503


    Sources:
    PharmGKB

  • PEMETREXED   ALK

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21642865


    Sources:
    CIViC

  • PEMETREXED   KRAS

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Pemetrexed + GSK1120212
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type predicted – sensitive

    PMIDs:
    27876675


    Sources:
    JAX-CKB CIViC

  • PEMETREXED   PTEN

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Pemetrexed + Sorafenib
    Indication/Tumor Type Advanced Solid Tumor
    Response Type predicted – sensitive

    PMIDs:
    27213589


    Sources:
    JAX-CKB

  • PEMETREXED   ABCC2

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • PEMETREXED   EGFR

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24636847 31605797


    Sources:
    CIViC

  • TEND: PEMETREXED

    • Version: 01-August-2011

    Alternate Names:
    PEMETREXED Primary Drug Name

    Drug Info:
    Year of Approval 2004
    Drug Class antineoplastic agents

    Publications:

  • TdgClinicalTrial: PEMETREXED

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent
    Drug Class Small molecule
    FDA Approval not approved

    Publications:

  • DTC: PEMETREXED

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL225072 ChEMBL Drug ID

    Drug Info:

    Publications:
    Wang L et al., 2011, Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-glycinamide ribonucleotide formyltransferase., J Med Chem
    Wang L et al., 2015, 6-Substituted Pyrrolo[2,3-d]pyrimidine Thienoyl Regioisomers as Targeted Antifolates for Folate Receptor α and the Proton-Coupled Folate Transporter in Human Tumors., J Med Chem
    Mitchell-Ryan S et al., 2013, Discovery of 5-substituted pyrrolo[2,3-d]pyrimidine antifolates as dual-acting inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis: implications of inhibiting 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase to ampk activation and antitumor activity., J Med Chem

  • JAX-CKB: Pemetrexed

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Gandara et al., 2017, A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer., J Thorac Oncol
    Poklepovic et al., 2016, Phase I study of pemetrexed with sorafenib in advanced solid tumors., Oncotarget

  • PharmGKB: pemetrexed

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Corrigan A et al., 2014, Pharmacogenetics of pemetrexed combination therapy in lung cancer: pathway analysis reveals novel toxicity associations., Pharmacogenomics J
    Adjei AA et al., 2010, Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426., J Clin Oncol
    Goldman ID et al., 2002, Molecular, biochemical, and cellular pharmacology of pemetrexed., Semin Oncol

  • CIViC: PEMETREXED

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Yang JC et al., 2020, A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis., J Thorac Oncol
    Li et al., 2014, Response to pemetrexed rechallenge after acquired resistance of EGFR-TKI in a patient with advanced NSCLC., Lung Cancer
    Kasai et al., 2013, Thymidylate synthase gene copy number as a predictive marker for response to pemetrexed treatment of lung adenocarcinoma., Anticancer Res.

  • TTD: Pemetrexed

    • Version: 2020.06.01

    Alternate Names:
    D0Y4GO TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL225072

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • MyCancerGenomeClinicalTrial: PEMETREXED

    • Version: 30-February-2014

    Alternate Names:

    Drug Info:

    Publications:

  • ClearityFoundationClinicalTrial: PEMETREXED

    • Version: 15-June-2013

    Alternate Names:

    Drug Info:

    Publications:

  • ClearityFoundationBiomarkers: PEMETREXED

    • Version: 26-July-2013

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21